PET scan study for pulmonary arterial hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This study uses a special PET scan tracer (XBD173) to look at inflammation in the lungs of people with pulmonary arterial hypertension (PAH). It aims to understand the role of a protein called TSPO in PAH and may help guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of pulmonary arterial hypertension (PAH) that is either idiopathic, inherited, or linked to connective tissue disease, repaired congenital heart defect, or certain drugs.
- You have had a right heart catheterization showing specific pressures in your lungs and heart.
- You have an implanted device that monitors your heart rhythm and lung artery pressure.
- You can walk at least 50 meters in 6 minutes.
- You have been stable on at least two PAH medications for at least one month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures how much of a specific lung protein (TSPO) is present in people with pulmonary artery hypertension. The results may help researchers better understand the disease and guide future treatments.
This study uses a special PET scan to see how a drug (XBD173) binds to a protein in the lungs. It may help researchers understand inflammation in the lungs and find new ways to treat lung diseases.
This trial tests an experimental drug called XBD173 to see if it can reduce blood vessel inflammation and lower pressure in the lungs of people with pulmonary arterial hypertension (PAH). If you have a PAH diagnosis, are on two or more PAH medications, and already have a heart and lung monitor implanted, this study may be an option for you.
This trial uses a special MRI scan (using xenon gas) to see how well the lungs are working in people with pulmonary arterial hypertension (PAH). It aims to improve diagnosis and monitoring of PAH from connective tissue disease or unknown cause.
This trial tests a new medicine called sotatercept to see if it improves heart and lung blood vessel health in people with PAH. Participants will have special PET scans to measure changes.
This trial uses a special imaging technique (xenon MRI) to see how well the lungs are functioning in people with pulmonary arterial hypertension (PAH) who are being treated with the drug sotatercept. It aims to understand if the drug improves lung function.
Hear when a new PAH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.